Saturday, 27 January 2018

Free Share Market Intraday Tips for NSE 29th January 2018


DO NOT TRADE BEFORE 9:30 AM and do not Buy or Sell if the Buy above or sell below rates are not reached. Violation of the same may lead to losses. PLEASE READ THE INSTRUCTIONS PROVIDED IN THE LEFT SIDE before using this tips for trading.

MORE WILL UPDATE SOON!!

Stock Watch: 29 Jan - 2 Feb 2018--International Market

Expect to hear about the Brexit effect when recruitment agency SThree (STHR) posts its full-year results on Monday. A year on from the Brexit vote SThree, which provides specialist recruitment services in the science, technology, engineering and mathematics (STEM) industries, said the slowdown in hiring activity in the UK was weighing heavily on the market for City investment banking jobs.
  
It wasn’t alone then and it’s not alone now. According to the CBI/PwC Financial Services Survey just released, optimism in the financial services sector fell for the third consecutive quarter in 2017 in the three months to December,
While Brexit uncertainty still hangs heavily over the City of London, it will be interesting to see how the group has fared overall. Around 80% of its profits have typically been generated outside the UK and Ireland, from Europe and the US.
The collapse of Monarch and Air Berlin brought the potential fragility of Europe-based airlines in an over-crowded market to the forefront. So all eyes will be on Flybe Group (FLYB) which is due to give its trading update on Wednesday.
Back in October shares in the Exeter-based budget airline group fell 20% after it posted its second profit warning in a year. Blaming an over-supplied European market, it said first-half pre-tax profits would be in the range of £5 million to £10 million, down from a consensus estimate of £15 million. This compares with a £15.9 million adjusted pre-tax profit a year ago.
Over supply doesn’t appear to be bothering Jozsef Varadi though. So it will interesting to hear more of his plans when his Budapest-based low-cost carrier, Wizz Air (WIZZ), posts Q3 results on Wednesday. Varadi intends to go from the current 87 or so aircraft Wizz operates, to around 250 after securing a multi-billion dollar aircraft order in November.
Calling the move away from the traditional sales and leaseback model and into aircraft ownership a “game changer”, he said the move would make Wizz even more competitive. And competition is the name of the game.
When the final jet from the order is delivered in 2026 there will be around 250 aircraft in the Wizz fleet and that will have the company snapping at rival easyJet’s tailfins, in terms of aircraft numbers.
But aircraft numbers and easyJet aren’t its only targets. It also has an eye on filling the gap left behind by Monarch and AirBerlin, with plans to cash-in on the growing number of central and eastern European travellers. That will put it in direct competition with Ryanair.
Wizz wants to increase its own capacity by 23% by the end of 2018 and one way it could do this is by bidding for the four aircraft spaces left empty by Monarch at London Luton airport, where Wizz Air opened a UK base last year. Each space would give it scope to add between 20 and 24 additional routes from the UK to Europe.
Analysts at Investec are forecasting full-year pre-tax profits of £261 million to March 2018, up from £207 million in 2017.
You may not have heard of AIM-quoted Angle (AGL), but that could be about to change if its Parsortix system, which measures cancer levels in later stage prostate cancer sufferers, becomes widely used.
With one in three people worldwide expected to develop some form of cancer in their lifetime and over 90% of deaths actually arising from secondary cancers, the race is on to find ways to stop cancers spreading.
This is where Angle’s Parsortix system comes in. It is designed to be a companion diagnostic for major pharmaceuticals companies in helping to identify patients that will benefit from particular drugs that stop, or at least slow, the metastasis.
As well as cancer, Angle says its technology has the potential to be with several other important cell types in the future.
Staying with biotech and the treatment of cancer, on Tuesday we get full-year results from Oxford BioDynamics (OBD).This is another AIM-listed biotech company that works on the discovery and development of biomarkers. Earlier this month it signed a second agreement with a major US biopharmaceutical company to extend its development of predictive biomarkers for immuno-oncology (IO) therapies. These work by equipping the body's immune system with the tools to kill cancer cells.
So far, Oxford BioDynamics has entered into four agreements to discover and develop predictive biomarkers for IO therapeutics - two with pharmaceutical companies, one with a major US healthcare concern and the latest agreement with a major US biopharmaceutical company.  Its shares have risen almost 35% in the past year.
Then on Friday we hear from pharmaceuticals giant AstraZeneca (AZN).Its full-year results will give us an update on its many medicines with the potential to generate big sales, as well as those which more bearish analysts place no value on in the immune-oncology pipeline. Something of a Marmite stock, fans remain convinced that at least one of its cancer drugs in the late stage of development will kick-start an earnings recovery. We’ll have to wait until Friday to see whether the bulls or the bears are right.
Key company announcements in the week ahead 
Monday
Petra Diamonds Ltd (PDL)
Yu Group (YU.)
Conviviality (CVR)
Porvair (PRV)
SThree (STHR)
Tuesday
Domino’s Pizza group (DOM)
Oxford Biodynamics (OBD)
Filtronic (FTC)
PZ Cussons (PZC)
Wednesday
Angle (AGL)
Best of the Best (BOTB)
Joules group (JOUL)
Wizz Air Holdings (WIZZ)
Flybe Group (FLYB)
Britvic (BVC)
SSE (SSE)
Thursday
Royal Dutch Shell (RDSA and RDSB)
Rank Group (RNK) AG Barr (BAG)
Glencore (GLEN)
3i Group (III)
Friday
BT group (BT.A)
AstraZeneca (AZN)
Gem Diamonds Ltd (GEMD)
MORE WILL UPDATE SOON!!

Penny Stocks to Watch for January 2018:International Markets

Penny stocks limped into December, under performing other investments, with the majority of speculative capital pouring into red-hot blockchain and cryptocurrency plays. Small baskets of low-priced biotech and industrial metals lifted to monthly highs but the majority just ran in place or ticked lower, grinding through multi month consolidation patterns or entering new downtrends.

  

Sierra Oncology, Inc. (SRRA)
posted the most substantial gains on the December watch list, rising more than 30% to an 18-month high. That stock and four previous picks have been added to January’s penny stocks list because their technicals continue to forecast even higher prices. Also, the first penny stocks to watch list for 2018 includes three perennial laggards who have recently shifted out of traditional operations into blockchain technology. Keep in mind these are highly volatile issues that require well-honed risk management skills to avoid steep and painful losses.  

January will signal the most favorable seasonality of the year for small caps and low-priced stocks. The prior year’s laggards and beaten down issues often post their strongest yearly gains in the first quarter, for two reasons. First, tax loss selling ends on December 31, allowing weak performers to float higher. Second, winners get sold with equal fervor in January as market players take profits to incur capital gains exposure, often rotating into more speculative plays.

Penny Stocks to Keep Watching


1. Medical Transcription Billing, Corp. (MTBC)
MTBC
Medical Transcription Billing Corp
3.90
+8.63%
 

Medical Transcription Billing, Corp. (MTBC)
entered a steep decline after coming public at $5.00 in July 2014, posting lower lows into the second quarter of 2017 when it finally bottomed out at 29-cents. It surged to $3.84 less than three weeks later and pulled back, consolidating gains into a failed October breakout attempt. The stock has spent the last three months grinding sideways in the upper third of the 9-month trading range while the 200-day EMA continues to tick higher, predicting that resistance will break and lift the uptrend into an all-time high.


2. EVINE Live, Inc. (EVLV)
EVLV
EVINE Live Inc
1.30
-2.26%
 

EVINE Live, Inc. (EVLV)
rallied to a 4-year high at $8.73 in 2011 after dropping to an all-time low at 18-cents during the economic collapse. That level marked resistance at the top of a rectangle pattern that broke support at $1.40 in January 2016. The stock fell into a higher low at 41-cents in September 2016 and turned higher, reversing at the breakdown level into 2017, It bounced at 90-cents in August and is testing resistance once again, with a breakout predicting excellent upside that could test double digits.


3. Sierra Oncology, Inc. (SRRA
SRRA
Sierra Oncology Inc
3.44
+5.85%
 

Sierra Oncology, Inc. (SRRA)
posted an all-time high at $33.75 during its IPO session in July 2015 and turned sharply lower, dropping to an all-time low at $1.10 in June 2017. Committed buyers took control in July, generating an uptrend that’s nearly quadrupled the stock’s price in just six months. The rally is now filling the June 2016 gap between $6.70 and $2.96, raising odds for healthy upside into the fill price in coming months. On Balance Volume (OBV) has already reached an all-time high, predicting that price will continue to play catch-up.


4. Ladenburg Thalmann Financial Services, Inc. (LTS)
LTS
Ladenburg Thalmann Financial Services Inc
3.13
+1.95%
 

Ladenburg Thalmann Financial Services, Inc. (LTS)
 rallied to a 15-year high at $4.50 in October 2014 and entered a decline that posted lower lows into November 2016 when it bottomed out at $1.63. The stock bounced into range resistance at $2.80 one month later and pulled back, grinding out a higher low above $2.00 in May 2017. It broke out in October and has been crisscrossing resistance near the November 2015 high at $3.28 for the last 6-weeks. A buying spike above $3.50 should clear this obstacle, opening the door to a test of the 2014 high.


5. Limelight Networks, Inc. (LLNW)
LLNW
Limelight Networks Inc
4.36
+1.63%
 

Limelight Networks, Inc. (LLNW)
posted an all-time low at 90-cents in February 2016 and entered a new uptrend that remounted broken range support at $2.00 after the presidential election. The rally reached the 2015 high at $4.43 in October 2017, yielding a breakout that now favors additional upside into the 2010 high at $8.97. The uptick stalled above $6.00 in November, generating a decline that’s just filled the October breakaway gap at $4.50. This price action may signal a low-risk buying opportunity, ahead of a bounce that resumes the strong uptrend.

6. Nova Lifestyle, Inc. (NVFY)
NVFY
Nova Lifestyle Inc
2.40
+0.42%
 

Nova Lifestyle, Inc. (NVFY)
recently formed I Design Blockchain Technology, Inc., a wholly-owned subsidiary. The furniture maker came public at $2.05 in January 2013 and posted an all-time high at $10.35 one year later. The subsequent decline accelerated into July 2016, dumping the stock to an all-time low at 38-cents while a bounce into October ended at $5.15. It carved a higher low in the summer of 2017 and spiked to yearlong range resistance at $2.75 after the magical transformation, with a breakout favoring continued upside into last year’s high.





7. Long Blockchain, Corp. (LTEA)
LTEA
Long Blockchain Corp
6.44
-2.28%
 

Long Blockchain, Corp. (LTEA)
 formerly known as Long Island Iced Tea, Corp., rallied to $15.00 in February 2015 and sold off, finding support near $3.60 in 2016. It broke down in September 2017, dropping into December’s multi-year low at $1.70 just a few days before its name change triggered a furious pre-market rally into the mid-teens, testing the prior high. The stock opened the regular session in single digits and has been pulling back since that time. A Fibonacci grid stretched across the vertical uptick predicts a buying opportunity at the .786 retracement level near $3.40. As of Dec. 29, the stock is hovering just below the $5.00 penny stock threshold, it may not be a penny stock for long. 


8. Nxt-ID, Inc. (NXTD)
D
Dominion Energy Inc
75.50
-1.55%
 

Nxt-ID, Inc. (NXTD)
joined the blockchain bandwagon on December 20 when it announced the development of a cryptocurrency payment platform. It came public at $30 in 2013 and posted an all-time high at $72.50 one month later. A decline accelerated into December 2015, dropping the stock to $1.60 ahead of even lower lows into November 2017. A vertical rally spike and deep pullback followed the blockchain news while a Fibonacci grid stretched across the uptick predicts a buying opportunity at the .786 retracement level near $2.75.





9. Viking Therapeutics, Inc. (VKTX)
VKTX
Viking Therapeutics Inc
5.63
+11.93%
 

Viking Therapeutics, Inc. (VKTX)
came public at $8.50 in April 2015 and topped out at $10.00 just one month later. The subsequent downtrend found support just under a buck in November 2016, yielding an August 2017 test that completed a bullish double bottom reversal. Buying power exploded in September, lifting the stock into December’s 2-year high at $4.40. It’s been consolidating gains in a narrow trading band for the last three weeks and could head higher in January, lifting toward broken 2015 range support near $5.70.





10. Aptevo Therapeutics, Inc. (APVO)

APVO
Aptevo Therapeutics Inc
3.37
+0.60%
 )

Aptevo Therapeutics, Inc. (APVO)
spiked up to $50 shortly after entering the public exchanges at $8.00 in July 2016 and settled into a downtrend that found support at $1.75 in the first half of 2017. It broke down in August, dropping to an all-time low at $1.15 and remounted broken support in September, setting off fresh buying signals. The subsequent uptrend reached a 16-month high at $4.50 in early December and eased into a high tight pennant that could generate fresh upside to $7.50.



MORE WILL UPDATE SOON!!